WallStreetZenWallStreetZen

NASDAQ: GMAB
Genmab A Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Genmab A earnings were $1.5B for the trailing 12 months ending Sep 30, 2025, with 116.8% growth year over year. The latest GMAB earnings report on Sep 30, 2025 announced Q3 2025 earnings of $401.0M, up 19.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GMAB reported annual earnings of $1.1B, with 79.6% growth. The next GMAB earnings date is Feb 5, 2026.

GMAB past earnings growth

How has GMAB's earnings growth performed historically?

Company
116.79%
Industry
61.94%
Market
54.98%
GMAB's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
GMAB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
GMAB's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

GMAB earnings history

Current Revenue
$3.6B
Current Earnings
$1.5B
Current Profit Margin
41.4%

GMAB Return on Equity

Current Company
27.6%
Current Industry
-21.2%
Current Market
35.8%
GMAB's Return on Equity (27.4%)... subscribe to Premium to read more.
High Return on Equity Performance

GMAB undefined

Current Company
22.4%
Current Industry
-8.7%
GMAB is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when GMAB announces earnings.

GMAB undefined

Current Company
31.04%
Current Industry
-3.4%
GMAB has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GMAB vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
GMAB$2.00B$1.47B+14.02%$2.34
INCY$1.68B$1.19B+25.56%$6.04
UTHR$1.77B$1.27B+21.79%$28.48
RPRX$1.04B$764.96M-2.40%$1.76
BNTX-$69.88M-$664.65MN/A-$2.76
View Top Biotech Stocks

GMAB earnings dates

Next earnings date
Feb 5, 2026

Genmab A Earnings Reports & History FAQ

What were Genmab A's earnings last quarter?

On GMAB's earnings call on Invalid Date, Genmab A (NASDAQ: GMAB) reported Q3 2025 earnings per share (EPS) of $0.65, up 121.43% year over year. Total GMAB earnings for the quarter were $401.00 million. In the same quarter last year, Genmab A's earnings per share (EPS) was $0.29.

If you're new to stock investing, here's how to buy Genmab A stock.

When does Genmab A report earnings?

The next GMAB earnings date is Invalid Date. Add GMAB to your watchlist to be reminded of Genmab A's next earnings date.

Is Genmab A profitable or losing money?

As of the last Genmab A earnings report, Genmab A is currently profitable. Genmab A's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $1.48 billion, a 111.66% increase year over year.

What was GMAB's earnings growth in the past year?

As of Genmab A's earnings date in Invalid Date, Genmab A's earnings has grown 116.79% year over year. This is 54.85 percentage points higher than the US Biotechnology industry earnings growth rate of 61.94%. GMAB earnings in the past year totalled $1.47 billion.

What are Genmab A's earnings expectations?

The current EPS estimate for Genmab A's earnings report in Invalid Date is $0.43.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.